Literature DB >> 30527659

The prevalence of hepatitis B core antibody in vaccinated Chinese children: A hospital-based study.

Yu-Ting Yang1, Ai-Long Huang2, Yao Zhao3.   

Abstract

BACKGROUND & AIMS: After nearly 30 years of immunization, there is little known about the prevalence of hepatitis B core antibody (anti-HBc) in Chinese children. The clinical significance of anti-HBc would be more and more important. In this study, we had tried to analyse the prevalence of anti-HBc in vaccinated Chinese children, exploring the post-immunization status based on a large sample sized investigation.
METHODS: Proportions of anti-HBc were analysed among 215,627 hospitalized Chinese children immunized with HBV vaccination in this study.
RESULTS: The proportions of anti-HBc were divided into 3 stages: 36.6% in 0-year-old group, followed by 1- to 10-year-old which stayed relatively stable (5.69 ± 0.40%, [4.86-6.28%]), and significant increasing within 11- to 16-year-old (7.80 ± 1.24%, [6.62-9.74%]), meanwhile, similar changes of HBsAg were showed in the corresponding ages, and significantly increased in children older than 9-year (1.40%, [1.00-2.04%]), comparing with 0.30% in 0-year-old, 0.55 ± 0.13% (0.30-0.64%) in 1- to 9-year-old. The average level of anti-HBc maintains 5.99% in children aged 1- to 16-year with 0.63% for HBsAg.
CONCLUSION: This is the first study of the prevalence of anti-HBc in vaccinated Chinese children: 36.6% of anti-HBc-positivity was found in 0-year-old group, which could be maternal in origin. Relatively high prevalence of anti-HBc may not be ignored in children aged 1- to 16-year-old. Strangely, our data also showed that HBV breakthrough infection would occur in immunized Chinese children older than 9-year-old, and more attention is needed on those children.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatitis B core antibody; Serosurvey; Vaccinated children

Mesh:

Substances:

Year:  2018        PMID: 30527659     DOI: 10.1016/j.vaccine.2018.11.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Long-term protection at 20-31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community.

Authors:  Jing-Chen Ma; Zhi-Wei Wu; Hai-Song Zhou; Zhao Gao; Zhi-Yong Hao; Fei Jin; Yan-Hong Zhang; Min-Jie Li; Feng Wang; Qi Li; Sheng-Li Bi; Yu-Liang Zhao
Journal:  Hum Vaccin Immunother       Date:  2019-08-29       Impact factor: 3.452

2.  Changing trends in seroprevalence rates of transfusion-transmitted diseases among blood donors in Jordan.

Authors:  Lina Souan; Mahmoud Siag; Hala Al-Salahat; Tareq Al-Atrash; Maher A Sughayer
Journal:  BMC Infect Dis       Date:  2021-05-31       Impact factor: 3.090

3.  Complementary Presence of HBV Humoral and T-cell Response Provides Protective Immunity after Neonatal Immunization.

Authors:  Yunmei Huang; Yuting Yang; Tingting Wu; Zhiyu Li; Hongmei Xu; Ailong Huang; Yao Zhao
Journal:  J Clin Transl Hepatol       Date:  2022-01-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.